Patents by Inventor Wenyan Yu
Wenyan Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952575Abstract: A transaminase mutant and use hereof, the amino acid sequence of the transaminase mutant is an amino acid sequence in which the amino acid sequence as represented by SEQ ID NO: 1 is mutated, the mutated amino acid position being one or more selected from among F89, K193, P243, V234, I262, Q280, V379, R416, A417 and C418. The enzymatic activity and/or stability of the transaminase mutant is improved.Type: GrantFiled: November 15, 2017Date of Patent: April 9, 2024Assignee: ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTDInventors: Hao Hong, Gage James, Jiangping Lu, Xingfu Xu, Wenyan Yu, Xin Huang, Yulei Ma, Yibing Cheng
-
Patent number: 11939708Abstract: Described herein is a weft-knitted spacer fabric and a preparation method thereof, a polyurethane foam composite material including the fabric, a preparation method of the composite material and its use in shoe materials. The weft-knitted spacer fabric consists of an upper surface layer, intermediate spacer yarns, and a lower surface layer, and the upper surface and the lower surface layer are connected by the tuck of the spacer yarns in the upper surface and the lower surface layer to form a three-dimensional structure in an integrated manner. The different selected tuck needle changes the connecting distance and the number of connections of the tuck, and the thickness of the spacer fabric and the arrangement density of the spacer yarns are changed by the action of the upper and lower surface layers of elastic yarns.Type: GrantFiled: April 8, 2019Date of Patent: March 26, 2024Assignee: BASF SEInventors: Xiao Yu Sun, Xiaojun Wu, Li Chao Zhu, Ren Zheng Zhang, Wenyan Zhu, Xueli Hu, Hairu Long
-
Publication number: 20240076627Abstract: A WAYNE293 LVPRO cell adapted to a serum-free medium environment, and applications thereof are provided. The human embryonic kidney cell WAYNE 293 is preserved in China General Microbiological Culture Collection Center (CGMCC) on May 24, 2021, the address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, No. 1 Yard, Beichen West Road, Chaoyang District, Beijing, the postal code is 100101, and the preservation number is CGMCC No. 22348. The human embryonic kidney cell WAYNE 293 may be derived from suspension culture of HEK293 cells in a serum-free medium free of an anti-agglomeration agent, has the characteristics of short doubling time, high growth density, high virus packaging efficiency, and is an important support for industrial development in the field of cell and gene therapy.Type: ApplicationFiled: November 10, 2023Publication date: March 7, 2024Applicant: QUACELL BIOTECHNOLOGY, CO. LTD.Inventors: Xiaoyu YU, Honghui PAN, Jun YUAN, Wenyan XU, Guohao XIE, Fan WU
-
Patent number: 11827909Abstract: Provided are a proline hydroxylase and uses thereof. The proline hydroxylase comprises having the amino acid sequence of SEQ ID NO: 2 with the exception of a mutation of one or more amino acids; wherein the mutation of one or more amino acids must comprises E27K, and the mutation of one or more amino acids selected from the group consisting of: H14R, L16N, T25R, F26L, E27K, D30S, S33N, E34N, E34G, E34L, E34S, E34D, Y35W, Y35K, S37W, S37F, S37E, S37N, S37T, S37C, W40F, K41E, D54G, H55Q, S57L, I58T, I58Y, I58A, I58R, I58V, I58S, I58C, K86P, T91A, F95Y, C97Y, I98V, K106V, K106T, K106Q, F111S, K112E, K112R, S154A, K162E, L166M, I118F, I118V, I118R, H119R, H119F, I120V, K123D, K123N, K123Q, K123S, K123I, K123T, T130N, D134G, V135K, N165H, D173G, K209R, I223V and S225A, and having proline hydroxylase activity.Type: GrantFiled: December 10, 2020Date of Patent: November 28, 2023Assignees: ASYMCHEM LABORATORIES (TIANJIN) CO., LTD., ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD., TIANJIN ASYMCHEM PHARMACEUTICALS CO., LTD., ASYMCHEM LABORATORIES (FUXIN) CO., LTD., JILIN ASYMCHEM LABORATORIES CO., LTD.Inventors: Hao Hong, Gage James, Jiangping Lu, Na Zhang, Wenyan Yu, Fang Liu, Yanjun Li, Xin Huang, Juan Gao, Kejian Zhang, Yulei Ma, Junlu Wei
-
Patent number: 11359219Abstract: The invention provides a transaminase mutant and application thereof, wherein the amino acid sequence of the transaminase mutant is formed after mutation of the amino acid sequence as shown in SEQ ID NO: 1, and mutated amino acid sites comprise T7C+S47C sites. The transaminase mutant having the mutation sites can be further prepared into an immobilized enzyme through an immobilization technology, the immobilized enzyme has relatively high activity and high stability, can be recycled for multiple times, and is applicable to continuous flow reaction in a packed bed.Type: GrantFiled: February 5, 2018Date of Patent: June 14, 2022Assignee: ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTDInventors: Hao Hong, Gage James, Jiangping Lu, Xingfu Xu, Yuxia Cui, Na Zhang, Xuewu Dong, Wenyan Yu, Xin Huang, Mingmin Hao, Yulei Ma, Yibing Cheng, Jiadong Zhao
-
Patent number: 11162081Abstract: A ketoreductase mutant and use thereof are provided. The amino acid sequence of the ketoreductase mutant is an amino acid sequence obtained by mutation of the amino acid sequence shown in SEQ ID NO: 1, wherein the mutation at least comprises one of the following mutation sites: position 6, position 94, position 96, position 117, position 144, position 156, position 193, position 205, position 224, position 176, position 85 and position 108; alternatively, the amino acid sequence of the ketoreductase mutant has a mutation site in a mutated amino acid sequence and an amino acid sequence having 80% or more homology with the mutated amino acid sequence.Type: GrantFiled: January 22, 2018Date of Patent: November 2, 2021Assignee: JILIN ASYMCHEM LABORATORIES CO., LTD.Inventors: Hao Hong, Gage James, Jiangping Lu, Xingfu Xu, Wenyan Yu, Na Zhang, Yulei Ma, Yibing Cheng, Huiyan Mu
-
Publication number: 20210095262Abstract: Provided are a proline hydroxylase and uses thereof. The proline hydroxylase comprises having the amino acid sequence of SEQ ID NO: 2 with the exception of a mutation of one or more amino acids; wherein the mutation of one or more amino acids must comprises E27K, and the mutation of one or more amino acids selected from the group consisting of: H14R, L16N, T25R, F26L, E27K, D30S, S33N, E34N, E34G, E34L, E34S, E34D, Y35W, Y35K, S37W, S37F, S37E, S37N, S37T, S37C, W40F, K41E, D54G, H55Q, S57L, I58T, I58Y, I58A, I58R, I58V, I58S, I58C, K86P, T91A, F95Y, C97Y, I98V, K106V, K106T, K106Q, F111S, K112E, K112R, S154A, K162E, L166M, I118F, I118V, I118R, H119R, H119F, I120V, K123D, K123N, K123Q, K123S, K123I, K123T, T130N, D134G, V135K, N165H, D173G, K209R, I223V and S225A, and having proline hydroxylase activity.Type: ApplicationFiled: December 10, 2020Publication date: April 1, 2021Inventors: Hao HONG, Gage JAMES, Jiangping LU, Na ZHANG, Wenyan YU, Fang LIU, Yanjun LI, Xin HUANG, Juan GAO, Kejian ZHANG, Yulei MA, Junlu WEI
-
Patent number: 10961516Abstract: Provided are a proline hydroxylase and uses thereof. The proline hydroxylase comprises (a) a protein having the amino acid sequence as shown in SEQ ID NO: 2; (b) a protein having an amino acid sequence of SEQ HD NO: 2 with a mutation of one or more amino acids and having a proline hydroxylase activity; or (c) a protein retaining the mutation of one or more amino acids as in (b), and having the proline hydroxylase activity and having at least 78% homology with the amino acid sequence of the protein in (b). Protein having the amino acid sequence as shown in SEQ HD NO: 2 and mutants obtained by genetically engineering have higher catalytic specificity or significantly increased catalytic activity when compared to proline hydroxylases in prior art.Type: GrantFiled: November 4, 2016Date of Patent: March 30, 2021Assignees: ASYMCHEM LABORATORIES (TIANJIN) CO., LTD., ASYMCHEM LIFE SCIENCES (TIANJIN) CO., LTD., TIANJIN ASYMCHEM PHARMACEUTICALS CO., LTD., ASYMCHEM LABORATORIES (FUXIN) CO., LTD., JILIN ASYMCHEM LABORATORIES CO., LTD.Inventors: Hao Hong, Gage James, Jiangping Lu, Na Zhang, Wenyan Yu, Fang Liu, Yanjun Li, Xin Huang, Juan Gao, Kejian Zhang, Yulei Ma, Junlu Wei
-
Publication number: 20210054428Abstract: The invention provides a transaminase mutant and application thereof, wherein the amino acid sequence of the transaminase mutant is formed after mutation of the amino acid sequence as shown in SEQ ID NO: 1, and mutated amino acid sites comprise T7C+S47C sites. The transaminase mutant having the mutation sites can be further prepared into an immobilized enzyme through an immobilization technology, the immobilized enzyme has relatively high activity and high stability, can be recycled for multiple times, and is applicable to continuous flow reaction in a packed bed.Type: ApplicationFiled: February 5, 2018Publication date: February 25, 2021Inventors: Hao HONG, Gage JAMES, Jiangping LU, Xingfu XU, Yuxia CUI, Na ZHANG, Xuewu DONG, Wenyan YU, Xin HUANG, Mingmin HAO, Yulei MA, Yibing CHENG, Jiadong ZHAO
-
Publication number: 20200354694Abstract: A ketoreductase mutant and use thereof are provided. The amino acid sequence of the ketoreductase mutant is an amino acid sequence obtained by mutation of the amino acid sequence shown in SEQ ID NO: 1, wherein the mutation at least comprises one of the following mutation sites: position 6, position 94, position 96, position 117, position 144, position 156, position 193, position 205, position 224, position 176, position 85 and position 108; alternatively, the amino acid sequence of the ketoreductase mutant has a mutation site in a mutated amino acid sequence and an amino acid sequence having 80% or more homology with the mutated amino acid sequence.Type: ApplicationFiled: January 22, 2018Publication date: November 12, 2020Inventors: Hao HONG, Gage JAMES, Jiangping LU, Xingfu XU, Wenyan YU, Na ZHANG, Yulei MA, Yibing CHENG, Huiyan MU
-
Publication number: 20200239895Abstract: A transaminase mutant and use hereof, the amino acid sequence of the transaminase mutant is an amino acid sequence in which the amino acid sequence as represented by SEQ ID NO: 1 is mutated, the mutated amino acid position being one or more selected from among F89, K193, P243, V234, I262, Q280, V379, R416, A417 and C418. The enzymatic activity and/or stability of the transaminase mutant is improved.Type: ApplicationFiled: November 15, 2017Publication date: July 30, 2020Applicant: Asymchem Life Science (Tianjin) Co., LtdInventors: Hao HONG, Gage JAMES, Jiangping LU, Xingfu XU, Wenyan YU, Xin HUANG, Yulei MA, Yibing CHENG
-
Publication number: 20200199544Abstract: Provided are a proline hydroxylase and uses thereof. The proline hydroxylase comprises (a) a protein having the amino acid sequence as shown in SEQ ID NO: 2; (b) a protein having an amino acid sequence of SEQ HD NO: 2 with a mutation of one or more amino acids and having a proline hydroxylase activity; or (c) a protein retaining the mutation of one or more amino acids as in (b), and having the proline hydroxylase activity and having at least 78% homology with the amino acid sequence of the protein in (b). Protein having the amino acid sequence as shown in SEQ HD NO: 2 and mutants obtained by genetically engineering have higher catalytic specificity or significantly increased catalytic activity when compared to proline hydroxylases in prior art.Type: ApplicationFiled: November 4, 2016Publication date: June 25, 2020Inventors: Hao HONG, Gage JAMES, Jiangping LU, Na ZHANG, Wenyan YU, Fang LIU, Yanjun LI, Xin HUANG, Juan GAO, Kejian ZHANG, Yulei MA, Junlu WEI
-
Patent number: 10131883Abstract: The application provides a Diketoreductase (DKR) mutant, its nucleotide coding sequence, and an expression cassette, recombinant vector and host cell containing the sequence, as well as a method for application of the mutant to the preparation of 3R,5S-dicarbonyl compound. An ee value of the obtained 3R,5S-dicarbonyl compound is higher than 99%, and a de value is about 90%. The DKR mutant is a key pharmaceutical intermediate, and particularly provides an efficient catalyst for synthesis of a chiral dicarbonyl hexanoic acid chain of a statin drug.Type: GrantFiled: August 4, 2014Date of Patent: November 20, 2018Assignees: Asymchem Laboratories (Tianjin) Co., Ltd, Asymchem Life Science (Tianjin) Co., Ltd, Tianjin Asymchem Pharmaceutical Co., Ltd, Asymchem Laboratories (Fuxin) Co., Ltd, Jilin Asymchem Laboratories Co., LtdInventors: Hao Hong, James Gage, Feng Gao, Lihui Liu, Wenyan Yu, Fang Liu, Lina Guo, Na Zhang
-
Publication number: 20170152488Abstract: The application provides a Diketoreductase (DKR) mutant, its nucleotide coding sequence, and an expression cassette, recombinant vector and host cell containing the sequence, as well as a method for application of the mutant to the preparation of 3R,5S-dicarbonyl compound. An ee value of the obtained 3R,5S-dicarbonyl compound is higher than 99%, and a de value is about 90%. The DKR mutant is a key pharmaceutical intermediate, and particularly provides an efficient catalyst for synthesis of a chiral dicarbonyl hexanoic acid chain of a statin drug.Type: ApplicationFiled: August 4, 2014Publication date: June 1, 2017Applicants: ASYMCHEM LABORATORIES (TIANJIN) CO., LTD., ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD., TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD., ASYMCHEM LABORATORIES (FUXIN) CO., LTD., JILIN ASYMCHEM LABORATORIES CO., LTD.Inventors: Hao Hong, James Gage, Feng Gao, Lihui Liu, Wenyan Yu, Fang Liu, Lina Guo, Na Zhang